Cited by 1,677Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

Open access

Spranger, Stefani, Spaapen, Robbert M., Zha, Yuanyuan, Williams, Jason, Meng, Yuru, Ha, Thanh T., Gajewski, Thomas F.·2013·Science Translational Medicine

DOI 10.1126/scitranslmed.3006504PMC PMC4136707

Open this paper in CoChat — free account

Abstract

Tumor escape from immune-mediated destruction has been associated with immunosuppressive mechanisms that inhibit T cell activation. Although evidence for an active immune response, including infiltration with CD8(+) T cells, can be found in a subset of patients, those tumors are nonetheless not immunologically rejected. In the current report, we show that it is the subset of T cell-inflamed tumors that showed high expression of three defined immunosuppressive mechanisms: indoleamine-2,3-dioxygenase (IDO), PD-L1/B7-H1, and FoxP3(+) regulatory T cells (T(regs)), suggesting that these inhibitory pathways might serve as negative feedback mechanisms that followed, rather than preceded, CD8(+) T cell infiltration. Mechanistic studies in mice revealed that up-regulated expression of IDO and PD-L1, as well as recruitment of T(regs), in the tumor microenvironment depended on the presence of CD8(+) T cells. The former was driven by interferon-γ and the latter by a production of CCR4-binding chemokines along with a component of induced proliferation. Our results argue that these major immunosuppressive pathways are intrinsically driven by the immune system rather than being orchestrated by cancer cells, and imply that cancer immunotherapy approaches targeting negative regulatory immune checkpoints might be preferentially beneficial for patients with a preexisting T cell-inflamed tumor microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3006504

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137 · cited 1×
“Previous work has shown that antigen-presenting cells in the tumor microenvironment can be tolerogenic (37), and that some cytokines abundant in the tumor, such as IL-10, can inhibit dendritic cell activation and result in T cell anergy (38).”
Background
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
Background
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
Background
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Although direct CCL22 production by tumor cells in other cancer types also has been suggested (34), we did not detect CCL22 mRNA expression in a series of melanoma cell lines, arguing that in the melanoma context, it is likely derived from infiltrating nontumor stromal cells (13).”
Background
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · cited 1×
“Clinical strategies to counter these immunosuppressive pathways are currently being evaluated, already with encouraging early-phase clinical trial results (10–12).”
Background
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589 · cited 1×
“IDO is a tryptophanmetabolizing enzyme that has been shown to contribute to peripheral immunologic tolerance (25).”
Background
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“…in mouse models include extrinsic suppression of CD8 + effector cells by CD4 + CD25 + FoxP3 + regulatory T cells (T regs ) (6), metabolic deregulation via tryptophan catabolism by indoleamine-2,3-dioxygenase (IDO) (7), and engagement of the inhibitory receptor PD-1 by the ligand PD-L1/B7-H1 (8, 9).”
Background
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · cited 2×
“It has been speculated that clinical response to antibodies targeting the PD-L1/PD-1 interaction may end up being restricted to cases in which PD-L1 expression is associated with a CD8 + T cell infiltrate and therefore is likely blunting host immunity (32).”
Background

Show all 50 references

Sorted by citations

Items 101–200 of 1,001

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
He, J., Hu, Y., Hu, M., & Li, B. (2015) · Scientific Reports · doi:10.1038/srep13110 · Cited by 411
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 407
Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma
Spranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Yan, L., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 403
PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials
Madore, J., Vilain, R. E., Menzies, A. M., Kakavand, H., Wilmott, J. S., Hyman, J., Yearley, J. H., Kefford, R. F., Thompson, J. F., Long, G. V., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12340 · Cited by 403
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Soares, K. C., Rucki, A. A., Wu, A. A., Olino, K. L., Xiao, Q., Chai, Y., Wamwea, A., Bigelow, E. O., Lutz, E. R., Liu, L. L., et al. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000062 · Cited by 406
T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Trujillo, J., Sweis, R. F., Bao, R., & Luke, J. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0277 · Cited by 396
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
Xia, L., Liu, Y., & Wang, Y. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s05 · Cited by 397
“In fact, a concept of “hot” and “cold” TME has been introduced with different levels of immune checkpoint expression in different local regions [104].”
BackgroundInfluential
A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors
Wang, T., Wang, D., Yu, H., Feng, B., Zhou, F., Zhang, H., Zhou, L., Jiao, S., & Li, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-03915-4 · Cited by 394
Lymph node colonization induces tumor-immune tolerance to promote distant metastasis
Reticker-Flynn, N. E., Zhang, W., Belk, J. A., Basto, P. A., Escalante, N. K., Pilarowski, G. O. W., Bejnood, A., Martins, M. M., Kenkel, J. A., Linde, I. L., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.019 · Cited by 399
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 419
“IDO1 is overexpressed in a variety types of cancers including melanoma.(689) Low level of IDO1 in melanoma metastasis is associated with improved overall survival and could predict the outcome of metastatic melanoma patients with immunotherapies.”
Background
Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 389
Modulating the microbiome to improve therapeutic response in cancer
McQuade, J. L., Daniel, C. R., Helmink, B. A., & Wargo, J. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30952-5 · Cited by 376
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
Liu, Y., Zhou, N., Zhou, L., Wang, J., Zhou, Y., Zhang, T., Fang, Y., Deng, J., Gao, Y., Liang, X., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00850-9 · Cited by 372
Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Dovedi, S. J., Cheadle, E. J., Popple, A. L., Poon, E., Morrow, M., Stewart, R. A., Yusko, E. C., Sanders, C. M., Vignali, M., Emerson, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1673 · Cited by 381
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 366
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Zhang, A. W., McPherson, A., Milne, K., Kroeger, D. R., Hamilton, P. T., Miranda, A., Funnell, T., Gierc, N. S., de Souza, C. P. E., Laan, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.073 · Cited by 353
“To provide context, we also considered other known mechanisms of immune escape, including anatomic site, disruption of antigen presentation machinery (Yoshihama et al., 2016), and expression of immunosuppressive factors (Spranger et al., 2013; Rooney et al., 2015).”
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0356-4 · Cited by 356
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Zhou, J. M., Mahoney, K. M., Giobbie‐Hurder, A., Zhao, F., Lee, S., Liao, X., Rodig, S. J., Li, J., Wu, X., Butterfield, L. H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0329 · Cited by 365
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Sweis, R. F., Spranger, S., Bao, R., Paner, G. P., Stadler, W. M., Steinberg, G. D., & Gajewski, T. F. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0274 · Cited by 356
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Wang, Y., Shen, Y., Wang, S., Shen, Q., & Zhou, X. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.12.003 · Cited by 343
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Jiang, X., Yin, T., & Lu, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 344
Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors
Ye, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z. (2016) · ACS Nano · doi:10.1021/acsnano.6b04989 · Cited by 342
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Butterfield, L. H., & Najjar, Y. G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 372
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M. B., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 345
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & di Magliano, M. P. (2016) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 339
The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion
Mojić, M., Takeda, K., & Hayakawa, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010089 · Cited by 352
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
Dong, M. B., Wang, G., Chow, R. D., Ye, L., Zhu, L., Dai, X., Park, J. J., Kim, H. R., Errami, Y., Guzman, C. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.044 · Cited by 330
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Zingg, D., Arenas-Ramirez, N., Şahin, D., Rosalia, R. A., Antunes, A. T., Häusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 339
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
Bodor, J. N., Boumber, Y., & Borghaei, H. (2019) · Cancer · doi:10.1002/cncr.32468 · Cited by 338
Recent advances in non-small cell lung cancer targeted therapy; an update review
Araghi, M., Mannani, R., Maleki, A. H., Hamidi, A., Rostami, S. M., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02990-y · Cited by 374
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Sautès‐Fridman, C., Tartour, É., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 333
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Lemos, H. D. P., Mohamed, E. T., Huang, L., Ou, R., Pacholczyk, G. A., Arbab, A. S., Munn, D. H., & Mellor, A. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1456 · Cited by 325
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 327
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Triplett, T. A., Garrison, K. C., Marshall, N., Donkor, M., Blazeck, J., Lamb, C., Qerqez, A., Dekker, J. D., Tanno, Y., Lu, W.-C., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4180 · Cited by 321
First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Self-citation
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Hu, J., Yu, A., Othmane, B., Qiu, D., Li, H., Li, C., Liu, P., Ren, W., Chen, M., Gong, G., et al. (2021) · Theranostics · doi:10.7150/thno.53649 · Cited by 387
“Another critical characteristic of an inflamed TME is the upregulation of inhibitory immune checkpoints such as PD-L1/PD-1, which are driven by pre-infiltrating TIICs [61].”
PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor
Shi, L., Chen, L., Wu, C., Zhu, Y., Xu, B., Zheng, X. W., Sun, M., Wen, W., Dai, X., Yang, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1352 · Cited by 313
Oncolytic virus immunotherapy: future prospects for oncology
Raja, J. Y., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0458-z · Cited by 321
“Among these, upregulation of type I IFN has been recognized as the top marker associated with sensitivity to immunostimulatory agents [64, 73, 74].”
Background
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
Maibach, F., Sadozai, H., Jafari, S. M. S., Hunger, R. E., & Schenk, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02105 · Cited by 317
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 317
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Koyama, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002591 · Cited by 313
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Gabrielson, A. T., Wu, Y., Wang, H., Jiang, J., Kallakury, B., Gatalica, Z., Reddy, S. B., Kleiner, D. E., Fishbein, T., Johnson, L. B., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0110 · Cited by 309
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Balar, A. V., & Weber, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1954-6 · Cited by 300
A snapshot of the PD-1/PD-L1 pathway
Ghosh, C., Luong, G., & Sun, Y. (2021) · Journal of Cancer · doi:10.7150/jca.57334 · Cited by 303
“stimulation of antigen presentation in IFN-γ can also downregulate the activation of T-cells by inducing PD-L1 expression [75, 76].”
Background
Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization
Zhao, F. L., Xiao, C., Evans, K. S., Theivanthiran, T., DeVito, N. C., Holtzhausen, A., Liu, J., Liu, X., Boczkowski, D., Nair, S. K., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.004 · Cited by 293
Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer
Sugiyama, E., Togashi, Y., Takeuchi, Y., Shinya, S., Tada, Y., Kataoka, K., Tane, K., Sato, E., Ishii, G., Goto, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3937 · Cited by 295
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 300
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 297
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 288
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment
Gajewski, T. F., Corrales, L. P., Williams, J. B., Horton, B. L., Sivan, A., & Spranger, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 284
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H. D. P., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0106-z · Cited by 282
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
van den Ende, T., de Clercq, N. C., Henegouwen, M. I. V. B., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4443 · Cited by 279
“The release of IFNg by T cells can lead to upregulation of PD-L1 in the tumor microenvironment (26).”
Background
Gut microbiota modulate T cell trafficking into human colorectal cancer
Cremonesi, E., Governa, V., Garzon, J. F. G., Mele, V., Amicarella, F., Muraro, M. G., Trella, E., Galati-Fournier, V., Oertli, D., Däster, S. R., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313498 · Cited by 275
The STING pathway and the T cell-inflamed tumor microenvironment
Woo, S., Corrales, L. P., & Gajewski, T. F. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.003 · Cited by 275
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 270
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Calles, A., Liao, X., Sholl, L. M., Rodig, S. J., Freeman, G. J., Butaney, M., Lydon, C., Dahlberg, S. E., Hodi, F. S., Oxnard, G. R., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000687 · Cited by 273
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, L., Chevolet, I., & Krüse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 271
The role of hypoxia‐inducible factor 1 in tumor immune evasion
Li, Y., Wu, W., Wang, X., Fang, L., Adam, V., Nepovimová, E., Wu, Q., & Kuča, K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21771 · Cited by 276
“In melanoma metastases comprising CD8 T cells, the immunosuppressive factors IDO and PD‐L1 were observed to have higher expression levels, preventing T cell function.(92) The authors, in this context, focused their attention on two immunosuppressive molecules related to the CD8 T cell infiltration (PD‐L1 and IDO).”
Background
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
Lu, C., Paschall, A. V., Shi, H., Savage, N. M., Waller, J. L., Sabbatini, M. E., Oberlies, N. H., Pearce, C. J., & Liu, K. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw283 · Cited by 264
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy
Asrir, A., Tardiveau, C., Coudert, J., Laffont, R., Blanchard, L., Bellard, E., Veerman, K. M., Bettini, S., Lafouresse, F., Vina, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.002 · Cited by 286
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment
Habanjar, O., Bingula, R., Decombat, C., Diab‐Assaf, M., Caldefie‐Chezet, F., & Delort, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044002 · Cited by 287
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Qian, J., Wang, C., Wang, B., Yang, J., Wang, Y., Luo, F., Xu, J., Zhao, C. J., Liu, R., & Chu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1330-2 · Cited by 278
Novel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 264
Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
Hammerl, D., Martens, J. W. M., Timmermans, M., Smid, M., Trapman-Jansen, A. M., Foekens, R., Isaeva, O. I., Voorwerk, L., Balcioglu, H. E., Wijers, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25962-0 · Cited by 262
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells
Kumagai, S., Togashi, Y., Sakai, C., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Kinoshita, T., Yamamoto, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.016 · Cited by 260
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Nakamura, T., Sato, T., Endo, R., Sasaki, S., Takahashi, N., Sato, Y., Hyodo, M., Hayakawa, Y., & Harashima, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002852 · Cited by 268
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Cooper, Z. A., Juneja, V. R., Sage, P. T., Frederick, D. T., Piris, A., Mitra, D., Lo, J. A., Hodi, F. S., Freeman, G. J., Bosenberg, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0215 · Cited by 264
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
Ilié, M., Hofman, V., Dietel, M., Soria, J., & Hofman, P. M. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1910-4 · Cited by 258
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
Ott, P. A., Piha-Paul, S. A., Münster, P. N., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., Gomez‐Roca, C., Ejadi, S., Stein, M. N., Chan, E. W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx029 · Cited by 259
Biomarkers for immunotherapy response in head and neck cancer
Gavrielatou, N., Doumas, S., Economopoulou, P., Foukas, P. G., & Psyrri, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101977 · Cited by 256
IFN-γ: A cytokine at the right time, is in the right place
Burke, J. D., & Young, H. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.05.002 · Cited by 272
Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy
Hoch, T., Schulz, D., Eling, N., Gómez, J. M. M., Levesque, M. P., & Bodenmiller, B. (2022) · Science Immunology · doi:10.1126/sciimmunol.abk1692 · Cited by 253
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy
Theivanthiran, B., Evans, K. S., DeVito, N. C., Plebanek, M. P., Sturdivant, M., Wachsmuth, L. P., Salama, A. K. S., Kang, Y., Hsu, D. S., Balko, J. M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133055 · Cited by 255
“In view of the relationship between infiltrating T cells and the induction of PD-L1 in the tumor microenvironment via IFN signaling, we further conjectured that release of HSPs from tumors and stimulation of the NLRP3/ HSP70 signaling axis are dependent on PD-L1 upregulation (15).”
Background
Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
Yu, M., Peng, Z., Qin, M., Liu, Y., Wang, J., Zhang, C., Lin, J., Dong, T., Wang, L., Li, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.010 · Cited by 250
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Taube, J. M., Young, G. D., McMiller, T. L., Chen, S., Salas, J. T., Pritchard, T. S., Xu, H., Meeker, A. K., Fan, J., Cheadle, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0244 · Cited by 252
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Pan, C.-X., Liu, H., Robins, E., Song, W., Liu, D., Li, Z., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00862-w · Cited by 251
Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Musetti, S., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05893 · Cited by 240
Hallmarks of response to immune checkpoint blockade
Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 251
Role of indoleamine 2,3-dioxygenase in health and disease
Yeung, A. W. S., Terentis, A. C., King, N. J. C., & Thomas, S. R. (2015) · Clinical Science · doi:10.1042/cs20140392 · Cited by 244
Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
Balli, D., Rech, A. J., Stanger, B. Z., & Vonderheide, R. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2128 · Cited by 240
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications
Chen, Y., Zhang, Y. X., Lv, J.-W., Li, Y.-Q., Wang, Y., He, Q.-M., Yang, X.-J., Sun, Y. H., Mao, Y., Yun, J., et al. (2017) · Theranostics · doi:10.7150/thno.21471 · Cited by 234
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes
Zhu, J., de Tenbossche, C. P., Canè, S., Colau, D., van Baren, N., Lurquin, C., Schmitt‐Verhulst, A., Liljeström, P., Uyttenhove, C., & den Eynde, B. J. V. (2017) · Nature Communications · doi:10.1038/s41467-017-00784-1 · Cited by 237
Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
van Baren, N., & den Eynde, B. J. V. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00034 · Cited by 237
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Selby, M., Engelhardt, J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K. B., Yao, D., Quigley, M. M., Valle, J., Wang, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161779 · Cited by 236
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Lu, C., Redd, P. S., Lee, J. R., Savage, N. M., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 242
Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
Gowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J. C., Rizos, H., & Hersey, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123410 · Cited by 238
Prognostic significance of PD-L1 and PD-L2 in breast cancer
Baptista, M. Z., Sarian, L. O., Derchain, S., Pinto, G. A., & Vassallo, J. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.09.006 · Cited by 236
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Håkansson, L., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 235
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 232
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
Wang, G., Kang, X., Chen, K. S., Jehng, T., Jones, L. E., Chen, J., Huang, X. F., & Chen, S. (2020) · Nature Communications · doi:10.1038/s41467-020-15229-5 · Cited by 232
Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs
Brown, M. C., Holl, E. K., Boczkowski, D., Dobrikova, E. Y., Mosaheb, M., Chandramohan, V., Bigner, D. D., Gromeier, M., & Nair, S. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4220 · Cited by 228
Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
Cassetta, L., Bækkevold, E. S., Brandau, S., Bujko, A., Cassatella, M. A., Dorhoi, A., Krieg, C., Lin, A., Loré, K., Marini, O., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02302-2 · Cited by 235
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2
Incio, J., Ligibel, J. A., McManus, D. T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S. M., Vardam, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0945 · Cited by 222
Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Deng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224
Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication
Burugu, S., Asleh, K., & Nielsen, T. O. (2016) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 234

Authors: Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F.
Affiliations: University of Chicago (US)
Corresponding author: Spranger, Stefani
Spaapen, Robbert M.
Gajewski, Thomas F.
ORCID: Spranger, Stefani
Spaapen, Robbert M.
Zha, Yuanyuan
Williams, Jason
Gajewski, Thomas F.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-08-28
Volume: 5
Issue: 200
Pages: 200ra116-200ra116
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.3006504
PMC: PMC4136707
OpenAlex: W2136731993
Cited by: 1,677
References: 50
Citations by year: 2026: 49 · 2025: 76 · 2024: 112 · 2023: 122 · 2022: 136 · 2021: 173 · 2020: 158 · 2019: 162 · 2018: 171 · 2017: 176 · 2016: 155 · 2015: 111 · 2014: 70 · 2013: 6
FWCI: 61.01
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: melanoma, tumor microenvironment, PD-L1, indoleamine 2,3-dioxygenase, regulatory T cells, CD8+ T cells, immunosuppression, immune checkpoint, interferon-gamma, cancer immunotherapy, tumor immune evasion
MeSH terms: Animals, Humans, Interferon-gamma, Lymphocyte Activation, Melanoma, Melanoma, Experimental, Neoplasm Metastasis, Up-Regulation, CD8-Positive T-Lymphocytes, Chemokines, Xenograft Model Antitumor Assays, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks